Import Alert 66-60

(Note: This import alert represents the Agency's current guidance to FDA field personnel regarding the manufacturer(s) and/or products(s) at issue. It does not create or confer any rights for or on any person, and does not operate to bind FDA or the public).

Import Alert # 66-60
Published Date: 04/23/2019
Type: DWPE

Import Alert Name:

"Detention Without Physical Eamaintion of Certain Steroid Alternatives"

Reason for Alert:

Unapproved alternatives to anabolic steroids have commonly been found to present serious safety and effectiveness concerns. In February, 1991, anabolic steroids became controlled substances. This is one factor which has stimulated the market for imported steroid alternatives. Note: Charge statement revised on 04/23/2019.


Districts may detain without physical examination all shipments of finished dosage forms (both commercial and personal) of the cited unapproved products. Do not collect samples for laboratory analysis. Districts should determine whether the drugs are covered by a current approved NDA or IND. Those products covered by an approved NDA or IND should be released.

Bulk forms of these drugs may be detained under certain circumstances as misbranded drugs; however, prior to initiating any action against bulk pharmaceutical chemicals, contact CDER's Import/Export Branch.

Product Description:

Foreign manufactured unapproved drugs promoted as alternatives to certain anabolic steroids i.e.,

* Yohimbe Bark or Yohimbe Bark Extract
* Cyclofenil
* Gamma Hydroxybutyrate (GHB)
* Diosgenin
* Clenbuterol


"The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA) [Unapproved new drug, Section 505(a)]"




  • (60 D - - 99) Adrenocortical Steroid N.E.C.
    Notes: Yohimbe Bark or Yohimbe Bark Extract Cyclofenil Gamma Hydroxybutyrate (GHB) Diosgenin Clenbuterol